Alpha IVF sets up second facility in the Philippines
In a statement, the fertility care specialist said the new centre advances the group's mission to broaden access to assisted reproductive services across the region.
Alpha IVF said the centre would provide minimally invasive surgery in gynaecology, which is expected to contribute significantly to the centre's revenue.
'Tuguegarao, a rapidly developing urban hub in northern Luzon, has a substantially underserved healthcare sector, with a growing middle-income demographic and a catchment population of 23.2 million, our centre will be the first and only IVF facility in the northern half of Luzon – Philippines' most populous island – positioning us to meet the increasing demand for advanced fertility care.
'The upcoming centre, targeted to be operational by the fourth quarter of 2026 (4Q26), will strategically complement the group's upcoming centre in Manila, to be launched by October 2025, as it grows its footprint in the Philippines,' the company said.
Group managing director Datuk Dr Colin Lee Soon Soo said the expansion into Tuguegarao allowed the company 'to make a tangible difference where demand for fertility treatment is significant, but access is limited.'
'Our mission is to bridge these accessibility gaps, reflecting our disciplined approach to investing in strategic locations that allow us to deliver world-class care, empowering more families across South-East Asia to achieve their dream of parenthood,' he added.
Separately Alpha IVF announced that it achieved its highest-ever profit after tax and minority interests (patmi) of RM57.5mil in the financial year ended May 31, 2025 (FY25) – a 8.5% increase from RM52.9mil in the previous year.
'The strong bottom-line performance was supported by revenue growth of 5.5% to RM176.8mil in FY25 from RM167.6mil in the previous year, led by the group's Malaysia operations, particularly the foreign patient segment.'
The company said Malaysia operations contributed RM157.2mil, or 88.9% of the group's total revenue in FY25 – a 16% increase from RM135.5mil in the previous year, or 80.9% of the group's total revenue.
The group's Singapore operations contributed the remaining RM19.6mil, according to the statement.
In the fourth quarter ended May 31, 2025, the group's revenue rose 7% year-on-year to RM50mil from RM46.7mil previously, while patmi saw a 14.7% increase to RM16.1mil from RM14mil in the corresponding quarter of the previous year.
The group has declared a second interim dividend of 0.50 sen per share in respect of FY25, payable on Aug 29.
'Together with the first interim dividend of 0.50 sen per share paid on Dec 31, 2024, the total dividends for FY25 amount to one sen per share, representing a payout of RM48.6mil or 84.6% of patmi.
'This is well above the group's commitment to distribute at least 60% of its annual patmi for shareholders.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
29-07-2025
- The Star
Alpha IVF sets up second facility in the Philippines
PETALING JAYA: Alpha IVF Group Bhd is establishing a new full-fledged fertility treatment centre in Tuguegarao, the Philippines, marking the group's second planned facility in the country. In a statement, the fertility care specialist said the new centre advances the group's mission to broaden access to assisted reproductive services across the region. Alpha IVF said the centre would provide minimally invasive surgery in gynaecology, which is expected to contribute significantly to the centre's revenue. 'Tuguegarao, a rapidly developing urban hub in northern Luzon, has a substantially underserved healthcare sector, with a growing middle-income demographic and a catchment population of 23.2 million, our centre will be the first and only IVF facility in the northern half of Luzon – Philippines' most populous island – positioning us to meet the increasing demand for advanced fertility care. 'The upcoming centre, targeted to be operational by the fourth quarter of 2026 (4Q26), will strategically complement the group's upcoming centre in Manila, to be launched by October 2025, as it grows its footprint in the Philippines,' the company said. Group managing director Datuk Dr Colin Lee Soon Soo said the expansion into Tuguegarao allowed the company 'to make a tangible difference where demand for fertility treatment is significant, but access is limited.' 'Our mission is to bridge these accessibility gaps, reflecting our disciplined approach to investing in strategic locations that allow us to deliver world-class care, empowering more families across South-East Asia to achieve their dream of parenthood,' he added. Separately Alpha IVF announced that it achieved its highest-ever profit after tax and minority interests (patmi) of RM57.5mil in the financial year ended May 31, 2025 (FY25) – a 8.5% increase from RM52.9mil in the previous year. 'The strong bottom-line performance was supported by revenue growth of 5.5% to RM176.8mil in FY25 from RM167.6mil in the previous year, led by the group's Malaysia operations, particularly the foreign patient segment.' The company said Malaysia operations contributed RM157.2mil, or 88.9% of the group's total revenue in FY25 – a 16% increase from RM135.5mil in the previous year, or 80.9% of the group's total revenue. The group's Singapore operations contributed the remaining RM19.6mil, according to the statement. In the fourth quarter ended May 31, 2025, the group's revenue rose 7% year-on-year to RM50mil from RM46.7mil previously, while patmi saw a 14.7% increase to RM16.1mil from RM14mil in the corresponding quarter of the previous year. The group has declared a second interim dividend of 0.50 sen per share in respect of FY25, payable on Aug 29. 'Together with the first interim dividend of 0.50 sen per share paid on Dec 31, 2024, the total dividends for FY25 amount to one sen per share, representing a payout of RM48.6mil or 84.6% of patmi. 'This is well above the group's commitment to distribute at least 60% of its annual patmi for shareholders.'
The Sun
23-07-2025
- The Sun
Alpha IVF opens satellite clinic in Surabaya, its second in Indonesia
PETALING JAYA: Fertility care specialist Alpha IVF Group Bhd has opened its second satellite clinic in Surabaya, Indonesia, its second in the country. The expansion forms part of the group's initial public offering roadmap to establish four satellite clinics in Indonesia, strengthening its regional growth strategy and deepening its footprint in the country, which is one of the group's fastest-growing international markets. Group managing director Datuk Dr Colin Lee Soon Soo said Surabaya was strategically chosen to expand the company's reach into East and Central Java, where it sees strong potential for growth in fertility treatment. 'Our first satellite clinic in Jakarta began showing results in less than three months of operations, which gives us strong confidence in the scalability and effectiveness of our satellite model. 'We believe the Surabaya clinic will build on this momentum and further increase patient referrals to our flagship centres in Malaysia,' he said in a statement. The new clinic is strategically located within the Womba Women's and Children Specialist Clinic in Surabaya. Situatedin the heart of East Java, Surabaya – the second largest city in Indonesia after Jakarta – was selected to meet the growing demand for assisted reproductive services across the region, including nearby urban centres such as Solo, Semarang and Yogyakarta. The clinic will serve as a key referral and patient coordination centre, offering initial consultations and fertility assessments, while seamlessly connecting patients to Alpha IVF's flagship centres in Malaysia for comprehensive treatment. Alpha IVF's first Indonesian satellite clinic, located in Pantai Indah Kapuk, Jakarta, commenced operations in May and has already shown encouraging results. In less than three months, 29 couples have been referred to the group's Malaysia-based centres, demonstrating early validation of the group's regional strategy. Alpha IVF expects its Indonesia-based satellite clinics, including those in Jakarta and Surabaya, to make a meaningful contribution to cross-border patient volume and revenue growth. Apart from Indonesia, Alpha IVF currently operates in Malaysia, Singapore and China. The group has pioneered numerous innovations leading to improved pregnancy rates and is actively involved in utilising advanced artificial intelligence technology to enhance embryo selection for higher IVF success rates.
New Straits Times
08-06-2025
- New Straits Times
PR frenzy, poor fundamentals: Disappointing IPO darlings
KUALA LUMPUR: Over the past 18 months, Bursa Malaysia witnessed a surge in new listings, many accompanied by high expectations and polished narratives. Behind the scenes, public relations consultants and investment advisors played pivotal roles organising media briefings, analyst meetings and investor briefings to generate interest and drive early demand. However, as the dust settles, some of these companies have fallen short of their promises, with share prices slipping below IPO levels despite the initial fanfare. Here are three companies that illustrate the disconnect between pre-listing optimism and post-listing realities: Alpha IVF Group Bhd •Recent Price: 28 sen (as of June 6) Alpha IVF, a fertility services provider, made its debut on Bursa Malaysia with a compelling narrative centred around expanding fertility awareness and clinical capabilities. The company positioned itself as a beacon of hope for couples struggling to conceive, backed by cutting-edge technologies and a regional footprint. Public relations consultants heavily promoted the IPO, emphasising emotional branding - stories of successful IVF journeys, warm imagery of smiling babies - and reassuring interviews with founders and doctors. Investor briefings were held, reinforcing the company's regional growth story. The IPO was oversubscribed, and the stock saw a slight uptick upon listing. However, the honeymoon phase was short-lived. Analysts began to question the valuation multiples, especially given the thin margins and rising operational costs of running fertility centres. The company's expansion plans, initially perceived as bold, began to look like expensive bets in a niche and price-sensitive market. Despite the promotional efforts, Alpha IVF's share price gradually declined, slipping below its IPO price and staying there. Notably, the IPO price of RM0.32 corresponded to a price-to-earnings (P/E) ratio of 21.92x, based on a net profit of RM54.79 million and earnings per share (EPS) of 1.46 sen for the financial year ended May 31, 2023. This valuation was higher than the industry's average P/E ratio, raising concerns about the company's valuation amidst the optimism. CPE Technology Bhd •IPO Price: RM1.07 •Recent Price: 71 sen (as of June 6) CPE's entry into Bursa was anything but quiet. As a precision engineering company with clients in the semiconductor, life sciences, and industrial automation sectors, it was touted as a proxy for Malaysia's high-tech ambitions. The IPO narrative leaned heavily on its global supply chain connections, particularly its exports to the US, Europe and China. In the weeks leading up to its listing, CPE's name was everywhere. PR consultants rolled out a carefully staged campaign: glossy investor kits were circulated, media interviews were arranged with top executives, and photos of high-tech assembly lines flooded financial pages. There were even organised tours for analysts and key fund managers to CPE's Johor-based facilities, complete with safety helmets, walkthroughs, and sales pitch presentations over coffee. The message was clear: CPE was not just another component maker - it was a growth story in a fast-evolving tech ecosystem. Investors initially responded with enthusiasm. The IPO was oversubscribed, and there was buzz about CPE being well-positioned to ride the next wave of industrial demand. But reality, as it often does, proved more complicated. Just a few quarters in, cracks began to appear. Order flows from major clients slowed as the global tech sector cooled. Margins came under pressure, not least due to rising raw material costs and a strong US dollar. Earnings missed early projections, and suddenly, the glow around CPE started to fade. The same analysts who had attended the factory tours began to revise their outlooks. Despite the polished communications campaign and well-managed listing strategy, CPE's share price drifted below its IPO level. The company had a credible story - but not enough momentum to keep the market convinced. DXN Holdings Bhd •IPO Price: 70 sen •Recent Price: 50 sen (as of June 6) DXN's return to the stock market after years in private hands was framed as a rebirth. PR consultants spoke of a "new chapter" for the direct-selling giant, with aggressive outreach to media and investor groups. Yet, cracks began to appear when earnings underwhelmed and overseas sales growth slowed. Despite the well-orchestrated relisting campaign, investors began to question whether DXN's golden era was behind it. Conclusion: Hype Fades, Fundamentals Remain Industry observers said new IPOs often arrive on a wave of excitement, backed by slick presentations, aggressive PR campaigns, and promises of untapped potential. But investors must learn to separate story from substance. Just because a stock is trending or being heavily marketed doesn't mean it's a good buy. PR blitzes can create temporary buzz, but they can't sustain valuations if earnings disappoint and growth stalls. The observers said the message is clear: don't get carried away by headlines or hype, and stick to fundamentals, scrutinise the financials and invest with discipline.
